NewLink Genetics (NASDAQ:NLNK) Cut to Strong Sell at ValuEngine
NLNK has been the topic of a number of other research reports. Zacks Investment Research cut NewLink Genetics from a buy rating to a hold rating in a research note on Wednesday, October 2nd. Bank of America lowered NewLink Genetics from a neutral rating to an underperform rating in a report on Friday, January 3rd.
NLNK traded down $0.09 during trading hours on Tuesday, reaching $1.91. The company’s stock had a trading volume of 19,240 shares, compared to its average volume of 2,201,269. NewLink Genetics has a 52 week low of $1.13 and a 52 week high of $3.60. The company’s 50-day moving average is $2.03 and its 200-day moving average is $1.67. The firm has a market cap of $74.62 million, a PE ratio of -1.56 and a beta of 1.19.
A number of hedge funds and other institutional investors have recently modified their holdings of NLNK. Renaissance Technologies LLC grew its holdings in NewLink Genetics by 7.6% in the 2nd quarter. Renaissance Technologies LLC now owns 2,927,465 shares of the biotechnology company’s stock valued at $4,333,000 after buying an additional 205,652 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in NewLink Genetics by 182.9% in the 2nd quarter. Tower Research Capital LLC TRC now owns 20,317 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 13,136 shares in the last quarter. Vanguard Group Inc. grew its holdings in NewLink Genetics by 30.5% in the 2nd quarter. Vanguard Group Inc. now owns 1,412,900 shares of the biotechnology company’s stock valued at $2,091,000 after buying an additional 330,510 shares in the last quarter. Paloma Partners Management Co acquired a new position in NewLink Genetics in the 2nd quarter valued at $191,000. Finally, Jane Street Group LLC acquired a new position in NewLink Genetics in the 2nd quarter valued at $178,000. 27.46% of the stock is currently owned by hedge funds and other institutional investors.
About NewLink Genetics
NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing Indoximod, an indoleamine-2, 3-dioxygenase (IDO) pathway inhibitor that is in clinical development in combination with other cancer therapeutics for patients with diffuse intrinsic pontine glioma, pediatric brain tumors, acute myeloid leukemia, and melanoma.
See Also: Which market index is the best?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.